Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...
A statistically significant reduction from baseline in Valsalva LVOT gradient was observed with mavacamten vs placebo at week 28. Topline data were announced from a phase 3 trial evaluating mavacamten ...
NEW ORLEANS -- The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), the phase III SCOUT-HCM trial showed. Already available to ...
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...
NEW ORLEANS, LA—Mavacamten (Camzyos; Bristol Myers Squibb) better reduces left ventricular outflow tract (LVOT) obstruction than placebo among adolescent patients with obstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results